nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-235-3-152-157nogr-3142Research ArticleМЕТАБОЛИЧЕСКИЙ СИНДРОМMETABOLIC SYNDROMEКатестатин и метаболический синдром у пациентов с гипертонической болезньюCathestatin and metabolic syndrome in patients with hypertensionhttps://orcid.org/0000-0002-9525-987XШванЛ. Ю.ShvanL. Yu.linashvan@yandex.ruhttps://orcid.org/0000-0003-1881-024XГубареваИ. В.GubarevaI. V.noemail@neicon.ruhttps://orcid.org/0009-0006-3715-9973ТокаревС. А.TokarevS. A.noemail@neicon.ruhttps://orcid.org/0000-0001-6824-3963ГубареваЕ. Ю.GubarevaE. Yu.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation20252910202503152157Copyright © Шван Л.Ю., Губарева И.В., Токарев С.А., Губарева Е.Ю., 20252025Шван Л.Ю., Губарева И.В., Токарев С.А., Губарева Е.Ю.Shvan L.Y., Gubareva I.V., Tokarev S.A., Gubareva E.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3142

Метаболический синдром (МС) является распространенным коморбидным состоянием у пациентов с гипертонической болезнью (ГБ), связанным с повышенным риском сердечно-сосудистых осложнений. Растущий интерес привлекает роль катестатина (CST) - продукта расщепления хромогранина А, обладающего вазодилатирующими, кардиопротективными и метаболическими свойствами. Цель настоящего обзора - проанализировать современные данные о взаимосвязи CST и компонентов МС у больных ГБ. Проведен систематический поиск в базах PubMed, Scopus, Web of Science. Критериям включения соответствовали 18 оригинальных исследований (общая выборка 2547 пациентов). Показано, что сниженный уровень CST ассоциирован с наличием МС (отношение шансов 2,47; 95% доверительный интервал 1,83-3,34), абдоминальным ожирением (r= -0,38; p<0,001), инсулинорезистентностью (r= -0,29; p<0,01) и дислипидемией (r= -0,25; p<0,05) независимо от пола, возраста и длительности ГБ. CST может рассматриваться как потенциальный биомаркер МС и терапевтическая мишень у пациентов высокого кардиометаболического риска. Необходимы дальнейшие проспективные исследования для оценки прогностической ценности CST и эффектов его целенаправленной коррекции.

Metabolic syndrome (MS) is a common comorbid condition in patients with hypertension (HTN), associated with an increased risk of cardiovascular complications. The role of catestatin (CST), a chromogranin A breakdown product with vasodilatory, cardioprotective, and metabolic properties, has attracted growing interest. The aim of this review is to analyze current data on the relationship between CST and MS components in patients with HTN. A systematic search was conducted in the PubMed, Scopus, and Web of Science databases. A total of 18 original studies (a total sample of 2,547 patients) met the inclusion criteria. It was shown that reduced CST level is associated with the presence of MS (odds ratio 2.47; 95% confidence interval 1.83-3.34), abdominal obesity (r= -0.38; p<0.001), insulin resistance (r= -0.29; p<0.01) and dyslipidemia (r= -0.25; p<0.05) regardless of gender, age and duration of hypertension. CST can be considered as a potential biomarker of MS and a therapeutic target in patients with high cardiometabolic risk.

катестатинметаболический синдромгипертоническая болезньинсулинорезистентностьабдоминальное ожирениекардиоваскулярный рискcatestatinmetabolic syndromehypertensioninsulin resistanceabdominal obesitycardiovascular riskReferencesAlberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009;120(16):1640-1645.Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009;120(16):1640-1645.Ellulu M.S., Patimah I., Khaza’ai H., Rahmat A., Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.Ellulu M.S., Patimah I., Khaza’ai H., Rahmat A., Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.Gu Q., Paulose-Ram R., Burt V.L., Kit B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no 177. Hyattsville, MD: National Center for Health Statistics. 2014.Gu Q., Paulose-Ram R., Burt V.L., Kit B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no 177. Hyattsville, MD: National Center for Health Statistics. 2014.Mahata S.K., Kiranmayi M., Mahapatra N.R. Catestatin: A Master Regulator of Cardiovascular Functions. Curr Med Chem. 2018;25(11):1352-1374.Mahata S.K., Kiranmayi M., Mahapatra N.R. Catestatin: A Master Regulator of Cardiovascular Functions. Curr Med Chem. 2018;25(11):1352-1374.Markov A.G., Ovchinnikova E.S., Shen Y. et al. The Role of Catestatin in the Regulation of Cardiovascular and Metabolic Functions. Front Neurosci. 2019;13:1094.Markov A.G., Ovchinnikova E.S., Shen Y. et al. The Role of Catestatin in the Regulation of Cardiovascular and Metabolic Functions. Front Neurosci. 2019;13:1094.Meng L., Ye X.J., Ding W.H., Yang Y., Di B.B., Liu H.J. Plasma catestatin level in patients with acute coronary syndrome and its correlation with ventricular remodelling. Postgrad Med J. 2011;87(1033):688-693.Meng L., Ye X.J., Ding W.H., Yang Y., Di B.B., Liu H.J. Plasma catestatin level in patients with acute coronary syndrome and its correlation with ventricular remodelling. Postgrad Med J. 2011;87(1033):688-693.Owen M.K., Noblet J.N., Sassoon D.J., Conteh A.M., Goodwill A.G., Tune J.D. Perivascular adipose tissue and coronary vascular disease. Arterioscler Thromb Vasc Biol. 2014;34(8):1643-1649.Owen M.K., Noblet J.N., Sassoon D.J., Conteh A.M., Goodwill A.G., Tune J.D. Perivascular adipose tissue and coronary vascular disease. Arterioscler Thromb Vasc Biol. 2014;34(8):1643-1649.Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399-2403.Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399-2403.Reinehr T. Metabolic Syndrome in Children and Adolescents: a Critical Approach Considering the Interaction between Pubertal Stage and Insulin Resistance. Curr Diab Rep. 2016;16(1):8.Reinehr T. Metabolic Syndrome in Children and Adolescents: a Critical Approach Considering the Interaction between Pubertal Stage and Insulin Resistance. Curr Diab Rep. 2016;16(1):8.Shah S.H., Newgard C.B.Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ Cardiovasc Genet. 2015;8(2):410-419.Shah S.H., Newgard C.B.Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ Cardiovasc Genet. 2015;8(2):410-419.Vanhoutte P.M., Shimokawa H., Feletou M., Tang E.H.C. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219(1):22-96.Vanhoutte P.M., Shimokawa H., Feletou M., Tang E.H.C. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219(1):22-96.Wang D., Govindaiah A., Liu R., De Arcangelis V., Cox C.L., Xiang Y.K. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 2010;24(9):3511-3521.Wang D., Govindaiah A., Liu R., De Arcangelis V., Cox C.L., Xiang Y.K. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 2010;24(9):3511-3521.Yoo Y.M., Lee C.J., Lee U., Kim Y.J. Nobiletin enhances adiponectin secretion from differentiated 3T3-L1 adipocytes via a MEK/ERK-dependent pathway. Biochem Biophys Res Commun. 2017;483(1):511-517.Yoo Y.M., Lee C.J., Lee U., Kim Y.J. Nobiletin enhances adiponectin secretion from differentiated 3T3-L1 adipocytes via a MEK/ERK-dependent pathway. Biochem Biophys Res Commun. 2017;483(1):511-517.Zhang X., Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61-73.Zhang X., Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61-73.Zhu Y., Liu Q., Zhou Z., Ikeda Y. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 2017;8(1):240.Zhu Y., Liu Q., Zhou Z., Ikeda Y. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 2017;8(1):240.

The authors declare that there are no conflicts of interest present.